Citations (31)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (12)
Louis F Rossiter, Winghan Jacqueline Kwong & Elizabeth Marrett. (2020) Healthcare Resource Use and Cost: The Impact of Adopting an Abuse-Deterrent Formulation of Extended Release Morphine. ClinicoEconomics and Outcomes Research 12, pages 35-44.
Read now
Read now
Mihran A. Yenikomshian, Alan G. White, Michael E. Carson, Zitong B. Jia, Mario R. Mendoza & Carl L. Roland. (2019) Modeling the potential impact of abuse-deterrent opioids on medical resource utilization. Journal of Medical Economics 22:10, pages 1073-1079.
Read now
Read now
Theodore J. Cicero, Mario Mendoza, Michael Cattaneo, Richard C. Dart, Jack Mardekian, Michael Polson, Carl L. Roland, Sidney H. Schnoll, Lynn R. Webster & Peter W. Park. (2019) Real-world misuse, abuse, and dependence of abuse-deterrent versus non-abuse-deterrent extended-release morphine in Medicaid non-cancer patients. Postgraduate Medicine 131:3, pages 225-229.
Read now
Read now
Elizabeth T. Masters, Arvind Ramaprasan, Jack Mardekian, Roy E. Palmer, David E. Gross, David Cronkite, Michael Von Korff & David S. Carrell. (2018) Natural Language Processing–Identified Problem Opioid Use and Its Associated Health Care Costs. Journal of Pain & Palliative Care Pharmacotherapy 32:2-3, pages 106-115.
Read now
Read now
Joseph V. Pergolizzi$suffix/text()$suffix/text(), Robert Taylor$suffix/text()$suffix/text(), Jo Ann LeQuang & Robert B. Raffa. (2018) What’s holding back abuse-deterrent opioid formulations? Considering 12 U.S. stakeholders. Expert Opinion on Drug Delivery 15:6, pages 567-576.
Read now
Read now
Joseph V. Pergolizzi$suffix/text()$suffix/text(), Robert B. Raffa, Robert Taylor$suffix/text()$suffix/text() & Steven Vacalis. (2018) Abuse-deterrent opioids: an update on current approaches and considerations. Current Medical Research and Opinion 34:4, pages 711-723.
Read now
Read now
Carl L. Roland, Joanita Lake & Gary M. Oderda. (2016) Prevalence of Prescription Opioid Misuse/Abuse as Determined by International Classification of Diseases Codes: A Systematic Review. Journal of Pain & Palliative Care Pharmacotherapy 30:4, pages 258-268.
Read now
Read now
Ron Goeree & Jeff Goeree. (2016) Cost-effectiveness analysis of oxycodone with naloxone versus oxycodone alone for the management of moderate-to-severe pain in patients with opioid-induced constipation in Canada. Journal of Medical Economics 19:3, pages 277-291.
Read now
Read now
Maciej Gasior, Mary Bond & Richard Malamut. (2016) Routes of abuse of prescription opioid analgesics: a review and assessment of the potential impact of abuse-deterrent formulations. Postgraduate Medicine 128:1, pages 85-96.
Read now
Read now
Amie Shei, Matthew Hirst, Noam Y Kirson, Caroline J Enloe, Howard G Birnbaum & William C N Dunlop. (2015) Estimating the health care burden of prescription opioid abuse in five European countries. ClinicoEconomics and Outcomes Research 7, pages 477-488.
Read now
Read now
Gary M. Oderda, Joanita Lake, Katja Rüdell, Carl L. Roland & Elizabeth T. Masters. (2015) Economic Burden of Prescription Opioid Misuse and Abuse: A Systematic Review. Journal of Pain & Palliative Care Pharmacotherapy 29:4, pages 388-400.
Read now
Read now
J. Bradford Rice, Noam Y. Kirson, Amie Shei, Caroline J. Enloe, Alice Kate G. Cummings, Howard G. Birnbaum, Pamela Holly & Rami Ben-Joseph. (2014) The Economic Burden of Diagnosed Opioid Abuse Among Commercially Insured Individuals. Postgraduate Medicine 126:4, pages 53-58.
Read now
Read now
Articles from other publishers (18)
Aziza Arifkhanova, Emily McCormick Kraus, Alia Al-Tayyib, Julie Taub, Annette Encinias, Dean McEwen, Arthur Davidson & Judith C. Shlay. (2021) Estimating costs of hospitalizations associated with opioid use disorder or opioid misuse at a large, urban safety-net hospital—Denver, Colorado, 2017. Drug and Alcohol Dependence 218, pages 108306.
Crossref
Crossref
Richard L. Rauck. (2019)
Mitigation of
IV
Abuse Through the Use of Abuse‐Deterrent Opioid Formulations: An Overview of Current Technologies
. Pain Practice 19:4, pages 443-454.
Crossref
Crossref
Amy Peacock, Briony Larance, Raimondo Bruno, Sallie-Anne Pearson, Nicholas A. Buckley, Michael Farrell & Louisa Degenhardt. (2019) Post-marketing studies of pharmaceutical opioid abuse-deterrent formulations: a framework for research design and reporting. Addiction 114:3, pages 389-399.
Crossref
Crossref
Carl L. RolandXiangyang YeVanessa StevensGary M. Oderda. (2019) The Prevalence and Cost of Medicare Beneficiaries Diagnosed and At Risk for Opioid Abuse, Dependence, and Poisoning. Journal of Managed Care & Specialty Pharmacy 25:1, pages 18-27.
Crossref
Crossref
Marcia Reinhart, Lauren M. Scarpati, Noam Y. Kirson, Cody Patton, Nina Shak & Jennifer G. Erensen. (2018) The Economic Burden of Abuse of Prescription Opioids: A Systematic Literature Review from 2012 to 2017. Applied Health Economics and Health Policy 16:5, pages 609-632.
Crossref
Crossref
Joshua P. Cohen, Mario Mendoza & Carl Roland. (2018) Challenges Involved in the Development and Delivery of Abuse-deterrent Formulations of Opioid Analgesics. Clinical Therapeutics 40:2, pages 334-344.
Crossref
Crossref
Lynn R. Webster, Carmela Pantaleon, Matthew Iverson, Michael D. Smith, Eric R. Kinzler & Stefan Aigner. (2018) Intranasal Pharmacokinetics of Morphine ARER, a Novel Abuse-Deterrent Formulation: Results from a Randomized, Double-Blind, Four-Way Crossover Study in Nondependent, Opioid-Experienced Subjects. Pain Research and Management 2018, pages 1-10.
Crossref
Crossref
Martin E Hale, Derek Moe, Mary Bond, Maciej Gasior & Richard Malamut. (2016) Abuse-deterrent formulations of prescription opioid analgesics in the management of chronic noncancer pain. Pain Management 6:5, pages 497-508.
Crossref
Crossref
Michael D. Smith, Lynn R. Webster, John Lawler, Karsten Lindhardt & Jeffrey M. Dayno. (2016) Human Abuse Potential of an Abuse-Deterrent (AD), Extended-Release (ER) Morphine Product Candidate (Morphine-ADER Injection-Molded Tablets) versus Extended-Release Morphine Administered Orally in Nondependent Recreational Opioid Users. Pain Medicine, pages pnw174.
Crossref
Crossref
Carmen Walter, Claudia Knothe & Jörn Lötsch. (2015) Abuse-Deterrent Opioid Formulations: Pharmacokinetic and Pharmacodynamic Considerations. Clinical Pharmacokinetics 55:7, pages 751-767.
Crossref
Crossref
Mark R. Jones, Martin J. Carney, Rachel J. Kaye, Amit Prabhakar & Alan D. Kaye. (2016) Drug Formulation Advances in Extended-Release Medications for Pain Control. Current Pain and Headache Reports 20:6.
Crossref
Crossref
Shellie L. Keast, Arthur Owora, Nancy Nesser & Kevin Farmer. (2016) Evaluation of Abuse-Deterrent or Tamper-Resistant Opioid Formulations on Overall Health Care Expenditures in a State Medicaid Program. Journal of Managed Care & Specialty Pharmacy 22:4, pages 347-356.
Crossref
Crossref
Amie Shei, J. Bradford Rice, Noam Y. Kirson, Katharine Bodnar, Caroline J. Enloe, Howard G. Birnbaum, Pamela Holly & Rami Ben-Joseph. (2015) Characteristics of High-Cost Patients Diagnosed with Opioid Abuse. Journal of Managed Care & Specialty Pharmacy 21:10, pages 902-912.
Crossref
Crossref
Noam Y. Kirson, Amie Shei, J. Bradford Rice, Caroline J. Enloe, Katharine Bodnar, Howard G. Birnbaum, Pamela Holly & Rami Ben-Joseph. (2015) The Burden of Undiagnosed Opioid Abuse Among Commercially Insured Individuals. Pain Medicine 16:7, pages 1325-1332.
Crossref
Crossref
Kyle Simon, Stacey L. Worthy, Michael C. Barnes & Benjamin Tarbell. (2015) Abuse-deterrent formulations: transitioning the pharmaceutical market to improve public health and safety. Therapeutic Advances in Drug Safety 6:2, pages 67-79.
Crossref
Crossref
Edward M. Sellers, Megan J. Shram & Kerri A. Schoedel. (2014) The US FDA Draft Guidance for Developing Abuse-Deterrent Opioid Analgesics: 2014 and Beyond. Pharmaceutical Medicine 28:6, pages 317-327.
Crossref
Crossref
Robert Twillman & Jeffrey Fudin. (2014) Potential Cost-Shifting and Hidden Costs and Risks in the Economic Analysis of Opioid Abuse-Deterrent Formulations. Pain Medicine 15:9, pages 1447-1449.
Crossref
Crossref
Noam Y. Kirson, Amie Shei, Alan G. White, Howard G. Birnbaum, Rami Ben-Joseph, Louis F. Rossiter & Edward Michna. (2014) Societal Economic Benefits Associated with an Extended-Release Opioid with Abuse-Deterrent Technology in the United States. Pain Medicine 15:9, pages 1450-1454.
Crossref
Crossref